Synonyms: 1-deamino,D-AVP | [deamino-Cys1,D-Arg8]vasopressin | dDAVP | Noctiva®
desmopressin is an approved drug (FDA (1978))
Compound class:
Peptide
Comment: Synthetic analogue of AVP. As is the case with many peptide molecules, there is ambiguity in the stereochemistry of the chemical structure of desmopressin. The structure shown here does not specify stereochemistry and so may vary from the representations shown on other resources linked to from the table above. PubChem also includes the following structures for desmopressin: (CID 16051933 and CID 5311065).
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
No information available. |
Summary of Clinical Use |
Desmopressin has long been used to treat bed-wetting, central cranial diabetes insipidus, and increased thirst and urination caused by head surgery or head trauma. In March 2017, the US FDA approved desmopressin acetate in a nasal spray formulation as the first treatment for nocturia due to nocturnal polyuria. A tablet formulation suitable for sublingual administration was FDA approved for this latter indication in June 2018. |
Mechanism Of Action and Pharmacodynamic Effects |
Desmopressin acetate works in nocturnal polyuria by increasing the absorption of water through the kidneys, which leads to less urine production. |